Discovery and validation of Lmj_04_BRCT domain, a novel therapeutic target: identification of candidate drugs for leishmaniasis
Since many of the currently available antileishmanial treatments exhibit toxicity, low effectiveness, and resistance, search and validation of new therapeutic targets allowing the development of innovative drugs have become a worldwide priority. This work presents a structure-based drug discovery st...
Main Authors: | Peña-Guerrero, J. (José), Fernández-Rubio, C. (Celia), Burguete-Mikeo, A. (Aroia), El-Dirany, R. (Rima), García-Sosa, A.T. (Alfonso T.), Nguewa, P.A. (Paul Alain) |
---|---|
Format: | info:eu-repo/semantics/article |
Language: | English |
Published: |
2022
|
Subjects: | |
Online Access: | https://hdl.handle.net/10171/62713 |
Similar Items
-
The BRCT domain from the homologue of the oncogene PES1 in Leishmania major (LmjPES) promotes malignancy and drug resistance in mammalian cells
by: Larrea, E. (Esther), et al.
Published: (2022) -
LmjF.22.0810 from Leishmania major Modulates the Th2-Type Immune Response and Is Involved in Leishmaniasis Outcome
by: Vacas, A. (Andrés), et al.
Published: (2023) -
Mining the proteome of Toxoplasma parasites seeking vaccine and diagnostic candidates
by: Rashidi, S. (Sajad), et al.
Published: (2022) -
Potential therapeutic targets shared between leishmaniasis and cancer
by: Rashidi, S. (Sajad), et al.
Published: (2021) -
Potential therapeutic targets shared between leishmaniasis and cancer
by: Rashidi, S. (Sajad), et al.
Published: (2022)